EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Peptide receptor radionuclide therapy (PRRT) and the pituitary: safety and efficacy

Francesco Ferraù, Elena Sofia Blanca, Carla Paola Costa iD, Salvatore Cannavò

Endocrine-Related Cancer · 2026

DOI: 10.1530/erc-26-0109 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, 2026. Verfasst von Francesco Ferraù und 3 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, University Hospital "G. Martino" , Messina, Italy. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Neuroendocrine Tumors, Radioisotopes, Octreotide. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptide receptor radionuclide therapy (PRRT) is an emerging and promising targeted treatment for aggressive pituitary neuroendocrine tumours (PitNETs) and pituitary carcinomas refractory to conventional therapies. Its use is supported by the frequent expression of somatostatin receptors (SSTRs), predominantly SSTR2, in pituitary tumour cells, enabling selective delivery of β-emitting radionuclides, such as 177Lu-DOTATATE and 90Y-DOTATOC, resulting in targeted antitumour and antisecretory effects. This narrative review summarises current limited evidence on PRRT efficacy and safety in aggressive pituitary tumours. Successful outcomes have been reported in some cases in terms of tumour growth reduction and/or hormonal reduction or relief of mass-effect-related symptoms. PRRT-related adverse events are mostly mild and transient, predominantly haematological, with clinically significant renal toxicity uncommon when amino acid nephroprotection is used. Preserved pituitary function and no clinically significant PRRT-induced hypopituitarism have been reported. Overall, PRRT represents a biologically rational and potentially effective option for selected patients with SSTR-positive aggressive PitNETs after failure of previous therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary NeoplasmsNeuroendocrine TumorsRadioisotopesOctreotideReceptors, PeptideReceptors, SomatostatinRadiopharmaceuticalsHumansAnimalsOrganometallic Compounds

Stichwörter der Autor:innen

PRRTPitNETaggressive pituitary tumourspeptide receptor radionuclide therapysomatostatin analogues

Substanzen

RadioisotopesOctreotideReceptors, PeptideReceptors, SomatostatinRadiopharmaceuticalsOrganometallic Compounds

Autor:innen und Institutionen

  • Endocrinology Unit, University Hospital "G. Martino" , Messina, Italy.
  • Department of Human Pathology of Adulthood and Childhood "G. Barresi", University of Messina , Messina, Italy.

ORCID-Profile: Carla Paola Costa

Zitieren

APA

Ferraù, F., Blanca, E. S., Costa, C. P., & Cannavò, S. (2026). Peptide receptor radionuclide therapy (PRRT) and the pituitary: safety and efficacy. Endocrine-Related Cancer. https://doi.org/10.1530/erc-26-0109

Vancouver

Ferraù F, Blanca ES, Costa CP, Cannavò S. Peptide receptor radionuclide therapy (PRRT) and the pituitary: safety and efficacy. Endocrine-Related Cancer. 2026. doi:10.1530/erc-26-0109

BibTeX
@article{Ferra2026,
  author = {Ferraù, Francesco and Blanca, Elena Sofia and Costa, Carla Paola and Cannavò, Salvatore},
  title = {Peptide receptor radionuclide therapy (PRRT) and the pituitary: safety and efficacy},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  doi = {10.1530/erc-26-0109}
}
Kostenlos starten →